We read with great interest the study by Kapetanakis et al, 1 which confirmed that clopidogrel administration increased the risk for hemostatic reexploration and also increased transfusion rates during and after off-pump coronary surgery. They and several other groups have previously reported similar results in patients on clopidogrel undergoing on-pump coronary surgery. The present recommendation in the accompanying editorial 2 is in line with the American College of Cardiology/ American Heart Association 2004 guideline update for coronary artery bypass graft surgery 3 . "If clinical circumstances permit, clopidogrel should be withheld for 5 days before performance of [coronary artery bypass graft] surgery" (p e394). In an earlier study by Kapetanakis et al (as well as in their present study 1 ), approximately 18% of the patients undergoing coronary surgery were treated with clopidogrel. Further, recent data indicate that up to 5% of all patients presenting for coronary surgery 4 may require urgent or immediate coronary artery bypass grafting after clopidogrel administration, and delaying surgery for the return of platelet function may not even be an option.
